X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11) 11
humans (10) 10
melanoma (9) 9
cancer (8) 8
female (8) 8
male (8) 8
middle aged (8) 8
oncology (8) 8
aged (7) 7
article (6) 6
care and treatment (6) 6
melanoma - drug therapy (6) 6
tumors (6) 6
adult (5) 5
aged, 80 and over (5) 5
immunotherapy (5) 5
metastasis (5) 5
braf (4) 4
cancer therapies (4) 4
hematology, oncology and palliative medicine (4) 4
melanoma - pathology (4) 4
molecular targeted therapy (4) 4
mutation (4) 4
patients (4) 4
skin neoplasms - drug therapy (4) 4
treatment outcome (4) 4
young adult (4) 4
analysis (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - therapeutic use (3) 3
cell lung-cancer (3) 3
clinical trials (3) 3
complications and side effects (3) 3
dermatology (3) 3
drug administration schedule (3) 3
medicine, research & experimental (3) 3
melanoma - genetics (3) 3
neoplasms - pathology (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
skin neoplasms - pathology (3) 3
squamous cell carcinoma (3) 3
survival (3) 3
1880-1956 (2) 2
20th century (2) 2
administration, oral (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antigens (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoptosis (2) 2
authors, american (2) 2
authors, american 20th century (2) 2
autophagy - drug effects (2) 2
basal cell carcinoma (2) 2
cell biology (2) 2
chemotherapy (2) 2
cytotoxicity (2) 2
drug approval (2) 2
erratum (2) 2
gorlin (2) 2
guidelines (2) 2
health aspects (2) 2
hedgehog (2) 2
henry louis (2) 2
internal medicine (2) 2
ligands (2) 2
lymphatic system (2) 2
map kinase kinase 1 - antagonists & inhibitors (2) 2
map kinase kinase 1 - metabolism (2) 2
map kinase kinase 2 - antagonists & inhibitors (2) 2
map kinase kinase 2 - metabolism (2) 2
mencken, h. l (2) 2
mencken, h. l. 1880-1956 (2) 2
mencken, h. l., 1880-1956 (2) 2
metastases (2) 2
mortality (2) 2
neoplasm staging (2) 2
neoplasms - drug therapy (2) 2
nivolumab (2) 2
pathway (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinase inhibitors - adverse effects (2) 2
pyridones - administration & dosage (2) 2
pyridones - adverse effects (2) 2
pyrimidinones - administration & dosage (2) 2
pyrimidinones - adverse effects (2) 2
research (2) 2
signal transduction - drug effects (2) 2
skin neoplasms - genetics (2) 2
smoothened (2) 2
surgery (2) 2
treatment (2) 2
united states (2) 2
vemurafenib (2) 2
vismodegib (2) 2
20. století (1) 1
6 ethyl 4,5 dihydro n [1 4 piperidinyl] 1 methyl 4 oxo 5 (1) 1
abridged index medicus (1) 1
acantholytic dyskeratosis (1) 1
accelerated approval (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
Journal Article
JAAD Case Reports, ISSN 2352-5126, 05/2018, Volume 4, Issue 4, pp. 379 - 381
Journal Article
Hematology/Oncology Clinics of North America, ISSN 0889-8588, 06/2009, Volume 23, Issue 3, pp. 599 - 618
Melanoma continues to be one of the most aggressive and morbid malignancies once metastatic. Overall survival for advanced unresectable melanoma has not... 
Drug | Microphthalmia-associated transcription factor | Angiogenesis | PI3K | Cell cycle | KIT | Melanoma | BRAF | MAPK | Molecular | Apoptosis | MALIGNANT MELANOCYTIC LESIONS | ORAL MEK INHIBITOR | SMALL-CELL LUNG | KIT PROTEIN EXPRESSION | DEPENDENT KINASE INHIBITOR | BH3 MIMETIC ABT-737 | METASTATIC MELANOMA | PHASE-II TRIAL | STAGE-IV MELANOMA | ONCOLOGY | HEMATOLOGY | GASTROINTESTINAL STROMAL TUMORS | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Oncogene Proteins - physiology | Autophagy - drug effects | Drug Delivery Systems | Cell Cycle Proteins - antagonists & inhibitors | Microphthalmia-Associated Transcription Factor - physiology | Angiogenesis Inhibitors - therapeutic use | Antineoplastic Agents - pharmacology | Cyclin-Dependent Kinases - antagonists & inhibitors | Cyclin-Dependent Kinases - physiology | Melanoma - metabolism | Transcription Factors - physiology | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Transcription Factors - antagonists & inhibitors | Forecasting | Microphthalmia-Associated Transcription Factor - antagonists & inhibitors | Oncogene Proteins - antagonists & inhibitors | Signal Transduction - drug effects | Melanoma - drug therapy | Cell Cycle - drug effects | Intracellular Signaling Peptides and Proteins - physiology | Cell Cycle Proteins - physiology
Journal Article
Science Translational Medicine, ISSN 1946-6234, 02/2014, Volume 6, Issue 224, pp. 224 - 224ra24
The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain... 
MEDICINE, RESEARCH & EXPERIMENTAL | CELL BIOLOGY
Journal Article
Biologics: Targets and Therapy, ISSN 1177-5475, 11/2015, Volume 9, pp. 129 - 140
Looks at the role of Vismodegib (GDC-0449), a smoothened inhibitor targeted at the hedgehog pathway, as the first US Food and Drug Association (FDA)-approved... 
Hedgehog | Smoothened | Basal cell carcinoma | Basal cell nevus syndrome | Vismodegib | Gorlin | Treatment | Cancer | Biologicals | Complications and side effects | Care and treatment | Squamous cell carcinoma | Analysis | Mortality | Research | Drug approval | Risk factors | Internal medicine | Dermatology | Surgery | Metastasis | Mutation | Kinases | Patients | Cancer therapies | Tumors | Skin cancer
Journal Article
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 10/2019, Volume 50, Issue 7, pp. 800 - 808
Summary Background Pembrolizumab immunotherapy has been associated with hepatotoxicity in 1%‐10% of oncology patients treated in clinical trials. Aim To... 
PHARMACOLOGY & PHARMACY | IMMUNE CHECKPOINT INHIBITORS | CAUSALITY ASSESSMENT | ACCELERATED APPROVAL | GASTROENTEROLOGY & HEPATOLOGY | Phosphatases | Metastasis | Bilirubin | Immunotherapy | Mortality | Liver | Corticoids | Alkaline phosphatase | Phenotypes | Alanine | Corticosteroids | Clinical trials | Patients | Metastases | Incidence | Pembrolizumab | Alanine transaminase | Remission | Hepatotoxicity | Injuries | Tumors | Bile
Journal Article
Autophagy, ISSN 1554-8627, 08/2014, Volume 10, Issue 8, pp. 1369 - 1379
Journal Article
by Amaria, Rodabe N and Menzies, Alexander M and Burton, Elizabeth M and Scolyer, Richard A and Tetzlaff, Michael T and Antdbacka, Robert and Ariyan, Charlotte and Bassett, Roland and Carter, Brett and Daud, Adil and Faries, Mark and Fecher, Leslie A and Flaherty, Keith T and Gershenwald, Jeffrey E and Hamid, Omid and Hong, Angela and Kirkwood, John M and Lo, Serigne and Margolin, Kim and Messina, Jane and Postow, Michael A and Rizos, Helen and Ross, Merrick I and Rozeman, Elisa A and Saw, Robyn P M and Sondak, Vernon and Sullivan, Ryan J and Taube, Janis M and Thompson, John F and van de Wiel, Bart A and Eggermont, Alexander M and Davies, Michael A and Andrews, Miles C and Berry, Donald A and Block, Matthew S and Boland, Genevieve M and Bollin, Kathryn B and Carlino, Matteo S and Carvajal, Richard D and Cohen, Jonathan and Davar, Diwakar and Delman, Keith A and Dummer, Reinhard and Farwell, Michael D and Fisher, David E and Fusi, Alberto and Glitza, Isabella C and de Gruijl, Tanja D and Gyorki, David E and Hauschild, Axel and Hieken, Tina J and Larkin, James and Lawson, David H and Lebbe, Celeste and Lee, Jeffrey E and Lowe, Michael C and Luke, Jason J and McArthur, Grant A and McDermott, David F and McQuade, Jennifer L and Mitchell, Tara C and Petrella, Teresa M and Prieto, Peter A and Puzanov, Igor and Robert, Caroline and Salama, April K and Sandhu, Shaneen and Schadendorf, Dirk and Shoushtari, Alexander N and Sosman, Jeffrey A and Swetter, Susan M and Tanabe, Ken K and Turajlic, Samra and Tyler, Douglas S and Woodman, Scott E and Wright, Frances C and Zager, Jonathan S and Ascierto, Paolo A and Spillane, Andrew J and van Akkooi, Alexander C J and Wargo, Jennifer A and Blank, Christian U and Tawbi, Hussein A and